213 related articles for article (PubMed ID: 17342745)
1. Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy.
Shimizu S; Kumagai J; Eishi Y; Uehara T; Kawakami S; Takizawa T; Koike M
Prostate; 2007 May; 67(6):645-52. PubMed ID: 17342745
[TBL] [Abstract][Full Text] [Related]
2. Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer.
Tokunaga M; Yasuda M; Osamura RY; Itoh J; Mukai M; Shima M; Usui Y; Masuda A; Miyakita H; Terachi T
Oncol Rep; 2005 Jun; 13(6):1081-7. PubMed ID: 15870925
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine cells in the prostatic carcinomas after neoadjuvant hormonal therapy.
Chen X; Okada H; Gotoh A; Arakawa S; Kamidono S
Kobe J Med Sci; 1997 Apr; 43(2):71-81. PubMed ID: 9385786
[TBL] [Abstract][Full Text] [Related]
4. [Impact of short-term neoadjuvant hormonal treatment on neuroendocrine differentiation in prostate carcinoma].
Li GZ; Zeng L; Zhang J; Yuan YM; Yang XY; Wang JH; Na YQ; Guo YL
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):493-5. PubMed ID: 14575578
[TBL] [Abstract][Full Text] [Related]
5. Difficulties in interpreting specimens after neoadjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation.
Civantos F
Mol Urol; 2000; 4(3):117-21; discussion 123. PubMed ID: 11062365
[TBL] [Abstract][Full Text] [Related]
6. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological significance of neoadjuvant hormonal therapy prior to radical prostatectomy: whole section analysis].
Uemura H; Cho M; Hirao Y; Konishi N
Hinyokika Kiyo; 2002 Nov; 48(11):719-23. PubMed ID: 12512148
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.
Hirano D; Okada Y; Minei S; Takimoto Y; Nemoto N
Eur Urol; 2004 May; 45(5):586-92; discussion 592. PubMed ID: 15082200
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer.
Ishida E; Nakamura M; Shimada K; Tasaki M; Konishi N
Pathobiology; 2009; 76(1):30-8. PubMed ID: 19188748
[TBL] [Abstract][Full Text] [Related]
11. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
12. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.
Miyata Y; Kanda S; Sakai H; Hakariya T; Kanetake H
Urology; 2005 Jun; 65(6):1238-43. PubMed ID: 15922418
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
15. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
Monsef N; Helczynski L; Lundwall A; PĂ„hlman S;
Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
[TBL] [Abstract][Full Text] [Related]
17. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy.
Krijnen JL; Bogdanowicz JF; Seldenrijk CA; Mulder PG; van der Kwast TH
J Urol; 1997 Jul; 158(1):171-4. PubMed ID: 9186347
[TBL] [Abstract][Full Text] [Related]
19. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
20. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]